Press Releases

Cell Source Retains Strategic Patent Advisor Dr. Michael B. Farber

NEW YORK, NY / ACCESSWIRE / May 20, 2015 / Cell Source, Inc. (OTCQB: CLCS) a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, announced today that Dr. Michael B. Farber, a Partner with Ditthavong & Steiner P.C. has been retained as Strategic Patent Advisor to the Company. The company's patented "Veto Cell" technology, is licensed exclusively from Yeda Research and Development Co. Ltd., the commercial arm of the Weizmann Institute of Science in Israel.

Itamar Shimrat, CEO of Cell Source stated, "Dr. Farber's extensive knowledge and deep insight will allow our company to maximize the value of our patent portfolio as we move towards new opportunities, either on our own and/or in collaboration with other important players in our field."

Dr. Farber's career has spanned the past 4 decades representing high-profile clients and cases focusing on licensing, litigation and general counseling for intellectual property matters. Dr. Farber stated that "the Cell Source patent portfolio and patented "Veto Cell" technology holds significant value to not only the company itself but also to those companies that Cell Source might partner and/or joint venture their technologies together."

Dr. Farber started his education at California Institute of Technology where he earned his B.S. in Biology (with Honors) then attended Harvard University where he earned his Ph.D. in Biochemistry & Molecular Biology. He earned his J.D. Magna Cum Laude from Southwestern University School of Law in Los Angeles.

About Cell Source, Inc.

Cell Source, Inc. (OTCQB: CLCS) a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine.

For more information go to www.cell-source.com.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. The actual future results of Cell Source, Inc. could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company's operations, inability to hire and retain qualified personnel, and changes in the general economic climate, as well as the risk factors disclosed in Cell Source, Inc.'s Form 10-K filed on March 13, 2015. Cell Source, Inc. may, in some cases, use terms such as "anticipates," "continue," "estimates," "predicts," "believes," "potential," "proposed," "expects," "plans," "intends," "may," "could," "should," "might," "will," or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by Cell Source, Inc. or any other person, that such forward-looking statements will be achieved. Cell Source, Inc. undertakes no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.

INVESTOR, MEDIA & GENERAL CORPORATE CONTACT:

Phone: +1 (646) 612-7554
Toll Free: +1 (888)-315-4650
Email: info@cell-source.com

SOURCE: Cell Source, Inc.